Global Pegfilgrastim Biosimilars Market Report 2024

Pegfilgrastim Biosimilars Global Market Report 2023 – By Application (Chemotherapy Treatment, Transplantation, Other Applications), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Mail-Order Pharmacies) – Market Size, Trends, And Global Forecast 2023-2032

Starting Price : $5000.00 | Pages : 250 | Published : January 2023 | Delivery Time: 2-3 business days | Format : pdf

Need assistance or more information before the purchase?

Enquire Before Buying
Pegfilgrastim Biosimilar Market

Proud Members Of

checkslacipN checkaoirsN checkscipN

Pegfilgrastim biosimilars refer to a biosimilar that is intended to be used in conjunction with supportive care for people with non-myeloid cancer. It can help prevent or treat infections brought on by myelosuppressive chemotherapy by promoting the formation of certain white blood cells.

The different applications of pegfilgrastim biosimilars are chemotherapy treatment, transplantation, and others. Chemotherapy is a cancer treatment that involves the administration of one or more anti-cancer medications as part of a defined protocol. The various distribution channels include hospital pharmacies, retail pharmacies, and mail-order pharmacies.

The global pegfilgrastim biosimilars market is segmented -

1) By Application: Chemotherapy Treatment, Transplantation, Other Applications

2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Mail-Order Pharmacies

The global pegfilgrastim biosimilars market size grew from $1.28 billion in 2022 to $1.41 billion in 2023 at a compound annual growth rate (CAGR) of 10.0%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The market size of the global pegfilgrastim biosimilars is expected to grow from $2.04 billion in 2027 at a CAGR of 9.7%.

Government initiatives for the development of biosimilars are expected to drive the pegfilgrastim biosimilars market. Governments worldwide are focusing on the development of biosimilars due to their cost-effective nature. The US Food and Drug Administration (FDA) launched a Biosimilar Action Plan, to increase treatment options. The Australian government is committed to the Biosimilar Awareness Initiative, and they improved their commitment by supporting the Generic and Biosimilar Medicines Association through a grant of $5 million to accept increased general biosimilar education and activities that promote the suitable dispensing, prescription, and use of biosimilar medicines. Hence, the government initiatives for the development of biosimilars aid in the increased production and awareness that, in turn, support the growth of the pegfilgrastim biosimilars market.

Major players in the pegfilgrastim biosimilars market report are Mylan, Biocon, Mundipharma, Pfizer, Sandoz, Coherus, Intas Pharmaceuticals, and Fresenius Kabi.

The FDA's low number of drug approvals hampered the pegfilgrastim biosimilar market during the forecast period. The market currently has only four drugs approved for treatment, thus restricting the growth of the market. This can be attributed to strict standards for manufacturing and high drug efficacy standards set by the regulatory bodies for approval of this therapy, thus increasing the time required for approval and limiting the growth of the market.

Companies in the pegfilgrastim biosimilar market are increasing their product innovation through strategic collaborations. To sustain themselves in the increasingly competitive market, companies are developing innovative products as well as sharing skills and expertise with other companies. While companies have long collaborated with academic and research institutions in this market by way of partnerships or out-licensing deals, this trend has been increasing over the past few years. For instance, in April 2020, Biocon, an India-based biopharmaceutical company, partnered with Mylan, a US-based generic and specialty pharmaceuticals company, to introduce Fulphila, a biosimilar pegfilgrastim, in Australia. Fulphila has been licenced by the Therapeutic Goods Administration for the therapy of oncology patients who have had chemotherapy to shorten the length of acute neutropenia and hence the risk of infection, as evidenced by febrile neutropenia.

In February 2022, Biocon Biologics Ltd., an India-based fully integrated biopharmaceutical company, acquired Viatris ' biosimilar business for $3.34 billion. Through this acquisition, BBL would be able to direct-market more of its existing and upcoming biosimilars. In order to maintain customer service and facilitate a smooth transition to BBL, Viatris is expected to provide commercial and other transition services with this acquisition for an anticipated two-year term. Viatris Inc is a US-based pharmaceutical and healthcare corporation that has co-developed a biosimilar of pegfilgrastim.

North America was the largest region in the pegfilgrastim biosimilars market in 2022. The Middle East is expected to be the fastest growing region in the global pegfilgrastim biosimilars market share during the forecast period. The regions covered in the pegfilgrastim biosimilars industry report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa.

The countries covered in the pegfilgrastim biosimilars market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA.

The pegfilgrastim biosimilars market consists of sales of fulphila, pelgraz, pelmeg, udenyca, ziextenzo, grasustek, fylnetra, and stimufend. Values in this market are "factory gate values," that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organisations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the chain or as part of other products.

The pegfilgrastim biosimilars market research report is one of a series of new reports from The Business Research Company that provides pegfilgrastim biosimilars market statistics, including pegfilgrastim biosimilars industry global market size, regional shares, competitors with a pegfilgrastim biosimilars market share, detailed pegfilgrastim biosimilars market segments, market trends and opportunities, and any further data you may need to thrive in the pegfilgrastim biosimilars industry. This pegfilgrastim biosimilars market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

    Table Of Contents

    1. Pegfilgrastim Biosimilars Market Executive Summary

    2. Table of Contents

    3. List of Figures

    4. List of Tables

    5. Report Structure

    6. Introduction

    6.1. Segmentation By Geography

    6.2. Segmentation By Application

    6.3. Segmentation By Distribution Channel

    7. Pegfilgrastim Biosimilars Market Characteristics

    7.1. Market Definition

    7.2. Market Segmentation By Application

    7.2.1. Chemotherapy Induced Neutropenia

    7.2.2. Transplantation

    7.2.3. Others

    7.3. Market Segmentation By Distribution Channel

    7.3.1. Hospital Pharmacies

    7.3.2. Retail Pharmacies

    7.3.3. Mail Order Pharmacies

    8. Pegfilgrastim Biosimilars Market Trends And Strategies

    8.1. Revised FDA Regulations To Facilitate Biosimilar Drug Development

    8.2. Robust Research & Development

    8.3. Large Number Of Strategic Partnerships

    8.4. Growing Mergers And Acquisitions

    8.5. Demand For Biosimilars In The Treatment Of Neutropenia

    9. Impact Of COVID-19 On Pegfilgrastim Biosimilars Market

    9.1. Impact On Global Pegfilgrastim Biosimilars Market

    9.2. Clinical Trial Delays

    9.3. Impact On Patients

    9.4. Impact On Major Players

    9.5. Future Outlook

    10. Global Pegfilgrastim Biosimilars Market Size And Growth

    10.1. Market Size

    10.2. Historic Market Growth, 2015 – 2020, Value ($ Million)

    10.2.1. Drivers Of The Market 2015 – 2020

    10.2.2. Restraints On The Market 2015 – 2020

    10.3. Forecast Market Growth, 2020 – 2025, 2030F, Value ($ Million)

    10.3.1. Drivers Of The Market 2020 – 2025

    10.3.2. Restraints On The Market 2020 – 2025

    11. Global Pegfilgrastim Biosimilars Market Segmentation

    11.1. Global Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, Value ($ Million)

    11.1.1. Chemotherapy Induced Neutropenia

    11.1.2. Transplantation

    11.1.3. Others

    11.2. Global Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic And Forecast, 2015 – 2020, 2025F, 2030F, Value ($ Million)

    11.2.1. Hospital Pharmacies

    11.2.2. Retail Pharmacies

    11.2.3. Mail-Order Pharmacies

    12. Pegfilgrastim Biosimilars Market, Regional And Country Analysis

    12.1. Global Pegfilgrastim Biosimilars Market, By Region, Historic and Forecast, 2015 – 2020, 2025F, 2030F, Value ($ Million)

    12.2. Global Pegfilgrastim Biosimilars Market, By Country, Historic and Forecast, 2015 – 2020, 2025F, 2030F, Value ($ Million)

    13. Asia-Pacific Pegfilgrastim Biosimilars Market

    13.1. Asia-Pacific Pegfilgrastim Biosimilars Market Overview

    13.1.1. Region Information

    13.1.2. Market Information

    13.1.3. Background Information

    13.1.4. Government Initiatives

    13.1.5. Regulations

    13.1.6. Regulatory Bodies

    13.1.7. Major Associations

    13.1.8. Taxes Levied

    13.1.9. Corporate Tax Structure

    13.1.10. Investments

    13.1.11. Major Companies

    13.2. Asia-Pacific Pegfilgrastim Biosimilars Market, Historic Market Growth, 2015 – 2020, Value ($ Million)

    13.3. Asia-Pacific Pegfilgrastim Biosimilars Market, Forecast Market Growth, 2020 – 2025, 2030F, Value ($ Million)

    13.4. Asia-Pacific Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, Value ($ Million)

    13.5. Asia-Pacific Pegfilgrastim Biosimilars Market: Country Analysis

    13.6. China Pegfilgrastim Biosimilars Market

    13.7. China Pegfilgrastim Biosimilars Market Overview

    13.7.1. Country Information

    13.7.2. Market Information

    13.7.3. Background Information

    13.7.4. Government Initiatives

    13.7.5. Regulations

    13.7.6. Regulatory Bodies

    13.7.7. Major Associations

    13.7.8. Taxes Levied

    13.7.9. Corporate Tax Structure

    13.7.10. Investments

    13.7.11. Major Companies

    13.8. China Pegfilgrastim Biosimilars Market, Forecast Market Growth, 2020 – 2025, 2030F, Value ($ Million)

    13.9. China Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, Value ($ Million)

    13.10. India Pegfilgrastim Biosimilars Market

    13.11. India Pegfilgrastim Biosimilars Market, Historic Market Growth, 2015 – 2020, Value ($ Million)

    13.12. India Pegfilgrastim Biosimilars Market, Forecast Market Growth, 2020 – 2025, 2030F, Value ($ Million)

    13.13. India Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, Value ($ Million)

    13.14. Japan Pegfilgrastim Biosimilars Market

    13.15. Japan Pegfilgrastim Biosimilars Market, Historic Market Growth, 2015 – 2020, Value ($ Million)

    13.16. Japan Pegfilgrastim Biosimilars Market, Forecast Market Growth, 2020 – 2025, 2030F, Value ($ Million)

    13.17. Japan Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, Value ($ Million)

    13.18. Australia Pegfilgrastim Biosimilars Market

    13.19. Australia Pegfilgrastim Biosimilars Market, Historic Market Growth, 2015 – 2020, Value ($ Million)

    13.20. Australia Pegfilgrastim Biosimilars Market, Forecast Market Growth, 2020 – 2025, 2030F, Value ($ Million)

    13.21. Australia Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, Value ($ Million)

    13.22. Indonesia Pegfilgrastim Biosimilars Market

    13.23. Indonesia Pegfilgrastim Biosimilars Market, Forecast Market Growth, 2020 – 2025, 2030F, Value ($ Million)

    13.24. Indonesia Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, Value ($ Million)

    13.25. South Korea Pegfilgrastim Biosimilars Market

    13.26. South Korea Pegfilgrastim Biosimilars Market, Forecast Market Growth, 2020 – 2025, 2030F, Value ($ Million)

    13.27. South Korea Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, Value ($ Million)

    14. Western Europe Pegfilgrastim Biosimilars Market

    14.1. Western Europe Pegfilgrastim Biosimilars Market Overview

    14.1.1. Region Information

    14.1.2. Market Information

    14.1.3. Background Information

    14.1.4. Government Initiatives

    14.1.5. Regulations

    14.1.6. Regulatory Bodies

    14.1.7. Major Associations

    14.1.8. Taxes levied

    14.1.9. Corporate Tax Structure

    14.1.10. Investments

    14.1.11. Major Companies

    14.2. Western Europe Pegfilgrastim Biosimilars Market, Historic Market Growth, 2015 – 2020, Value ($ Million)

    14.3. Western Europe Pegfilgrastim Biosimilars Market, Forecast Market Growth, 2020 – 2025, 2030F, Value ($ Million)

    14.4. Western Europe Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, Value ($ Million)

    14.5. Western Europe Pegfilgrastim Biosimilars Market: Country Analysis

    14.6. UK Pegfilgrastim Biosimilars Market

    14.7. UK Pegfilgrastim Biosimilars Market, Historic Market Growth, 2015 – 2020, Value ($ Million)

    14.8. UK Pegfilgrastim Biosimilars Market, Forecast Market Growth, 2020 – 2025, 2030F, Value ($ Million)

    14.9. UK Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, Value ($ Million)

    14.10. Germany Pegfilgrastim Biosimilars Market

    14.11. Germany Pegfilgrastim Biosimilars Market, Historic Market Growth, 2015 – 2020, Value ($ Million)

    14.12. Germany Pegfilgrastim Biosimilars Market, Forecast Market Growth, 2020 – 2025, 2030F, Value ($ Million)

    14.13. Germany Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, Value ($ Million)

    14.14. France Pegfilgrastim Biosimilars Market

    14.15. France Pegfilgrastim Biosimilars Market, Historic Market Growth, 2015 – 2020, Value ($ Million)

    14.16. France Pegfilgrastim Biosimilars Market, Forecast Market Growth, 2020 – 2025, 2030F, Value ($ Million)

    14.17. France Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, Value ($ Million)

    15. Eastern Europe Pegfilgrastim Biosimilars Market

    15.1. Eastern Europe Pegfilgrastim Biosimilars Market Overview

    15.1.1. Region Information

    15.1.2. Market Information

    15.1.3. Background Information

    15.1.4. Government Initiatives

    15.1.5. Regulations

    15.1.6. Regulatory Bodies

    15.1.7. Major Associations

    15.1.8. Taxes levied

    15.1.9. Corporate Tax Structure

    15.1.10. Investments

    15.1.11. Major Companies

    15.2. Eastern Europe Pegfilgrastim Biosimilars Market, Forecast Market Growth, 2020 – 2025, 2030F, Value ($ Million)

    15.3. Eastern Europe Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, Value ($ Million)

    15.4. Eastern Europe Pegfilgrastim Biosimilars Market: Country Analysis

    15.5. Russia Pegfilgrastim Biosimilars Market

    15.6. Russia Pegfilgrastim Biosimilars Market, Forecast Market Growth, 2020 – 2025, 2030F, Value ($ Million)

    15.7. Russia Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, Value ($ Million)

    16. North America Pegfilgrastim Biosimilars Market

    16.1. North America Pegfilgrastim Biosimilars Market Overview

    16.1.1. Region Information

    16.1.2. Market Information

    16.1.3. Background Information

    16.1.4. Government Initiatives

    16.1.5. Regulations

    16.1.6. Regulatory Bodies

    16.1.7. Major Associations

    16.1.8. Taxes Levied

    16.1.9. Corporate Tax Structure

    16.1.10. Investments

    16.1.11. Major Companies

    16.2. North America Pegfilgrastim Biosimilars Market, Historic Market Growth, 2015 – 2020, Value ($ Million)

    16.3. North America Pegfilgrastim Biosimilars Market, Forecast Market Growth, 2020 – 2025, 2030F, Value ($ Million)

    16.4. North America Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, Value ($ Million)

    16.5. North America Pegfilgrastim Biosimilars Market: Country Analysis

    16.6. USA Pegfilgrastim Biosimilars Market

    16.7. USA Pegfilgrastim Biosimilars Market Overview

    16.7.1. Country Information

    16.7.2. Market Information

    16.7.3. Background Information

    16.7.4. Government Initiatives

    16.7.5. Regulations

    16.7.6. Regulatory Bodies

    16.7.7. Major Associations

    16.7.8. Taxes Levied

    16.7.9. Corporate Tax Structure

    16.7.10. Investments

    16.7.11. Major Companies

    16.8. USA Pegfilgrastim Biosimilars Market, Historic Market Growth, 2015 – 2020, Value ($ Million)

    16.9. USA Pegfilgrastim Biosimilars Market, Forecast Market Growth, 2020 – 2025, 2030F, Value ($ Million)

    16.10. USA Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, Value ($ Million)

    17. South America Pegfilgrastim Biosimilars Market

    17.1. South America Pegfilgrastim Biosimilars Market Overview

    17.1.1. Region Information

    17.1.2. Market Information

    17.1.3. Background Information

    17.1.4. Government Initiatives

    17.1.5. Regulations

    17.1.6. Regulatory Bodies

    17.1.7. Major Associations

    17.1.8. Taxes Levied

    17.1.9. Corporate Tax Structure

    17.1.10. Investments

    17.1.11. Major Companies

    17.2. South America Pegfilgrastim Biosimilars Market, Forecast Market Growth, 2020 – 2025, 2030F, Value ($ Million)

    17.3. South America Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, Value ($ Million)

    17.4. South America Pegfilgrastim Biosimilars Market: Country Analysis

    17.5. Brazil Pegfilgrastim Biosimilars Market

    17.6. Brazil Pegfilgrastim Biosimilars Market, Forecast Market Growth, 2020 – 2025, 2030F, Value ($ Million)

    17.7. Brazil Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, Value ($ Million)

    18. Middle East Pegfilgrastim Biosimilars Market

    18.1. Middle East Pegfilgrastim Biosimilars Market Overview

    18.1.1. Region Information

    18.1.2. Market Information

    18.1.3. Background Information

    18.1.4. Government Initiatives

    18.1.5. Regulations

    18.1.6. Regulatory Bodies

    18.1.7. Major Associations

    18.1.8. Taxes levied

    18.1.9. Corporate Tax Structure

    18.1.10. Investments

    18.1.11. Major Companies

    18.2. Middle East Pegfilgrastim Biosimilars Market, Forecast Market Growth, 2020 – 2025, 2030F, Value ($ Million)

    18.3. Middle East Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, Value ($ Million)

    19. Africa Pegfilgrastim Biosimilars Market

    19.1. Africa Pegfilgrastim Biosimilars Market Overview

    19.1.1. Region Information

    19.1.2. Market Information

    19.1.3. Background Information

    19.1.4. Government Initiatives

    19.1.5. Regulations

    19.1.6. Regulatory Bodies

    19.1.7. Major Associations

    19.1.8. Taxes Levied

    19.1.9. Corporate Tax Structure

    19.1.10. Investments

    19.1.11. Major Companies

    19.2. Africa Pegfilgrastim Biosimilars Market, Forecast Market Growth, 2020 – 2025, 2030F, Value ($ Million)

    19.3. Africa Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, Value ($ Million)

    20. Global Pegfilgrastim Biosimilars Market Competitive Landscape

    20.1. Company Profiles

    20.2. Coherus Biosciences Inc.

    20.2.1. Company Overview

    20.2.2. Products And Services

    20.2.3. Business Strategy

    20.2.4. Financial Overview

    20.3. Sandoz (Novartis)

    20.3.1. Company Overview

    20.3.2. Products And Services

    20.3.3. Business Strategy

    20.3.4. Financial Overview

    20.4. Biocon

    20.4.1. Company Overview

    20.4.2. Products And Services

    20.4.3. Business Strategy

    20.4.4. Financial Overview

    20.5. Mylan

    20.5.1. Company Overview

    20.5.2. Products And Services

    20.5.3. Business Strategy

    20.5.4. Financial Overview

    20.6. Intas Biopharmaceuticals Ltd

    20.6.1. Company Overview

    20.6.2. Products And Services

    20.6.3. Business Strategy

    20.6.4. Financial Overview

    20.7. Mundipharma GmbH

    20.7.1. Company Overview

    20.7.2. Products And Services

    20.7.3. Business Strategy

    20.7.4. Financial Overview

    20.8. Dr. Reddy’s Laboratories

    20.8.1. Company Overview

    20.8.2. Products And Services

    20.8.3. Business Strategy

    20.8.4. Financial Overview

    20.9. Pfizer Inc.

    20.9.1. Company Overview

    20.9.2. Products And Services

    20.9.3. Business Strategy

    20.9.4. Financial Overview

    20.10. Emcure Pharmaceuticals (Gennova Biopharmaceuticals Ltd.)

    20.10.1. Company Overview

    20.10.2. Products And Services

    20.10.3. Financial Overview

    20.11. USV Private Limited

    20.11.1. Company Overview

    20.11.2. Products And Services

    20.11.3. Business Strategy

    20.11.4. Financial Overview

    21. Pegfilgrastim Biosimilars Market Pipeline Analysis

    22. Key Mergers And Acquisitions In The Pegfilgrastim Biosimilars Market

    22.1. AbCellera Acquired TetraGenetics

    22.2. Ligand Pharmaceuticals Acquired Pfenex

    22.3. True North Acquired Stake In Biocon Biologics

    22.4. Coherus BioSciences Inc Acquired Innovent Biologics Co. Ltd.

    22.5. Biocon Acquires Pfizer's R&D Facility To Boost Biosimilars Development

    22.6. AbbVie Acquired Allergan

    22.7. Kashiv Pharma Acquired Adello Biologics

    22.8. Mundipharma International Limited Acquired Cinfa Biotech

    22.9. Biocon Merged With Sandoz

    22.10. Fresenius Kabi Acquired The Biosimilars Business Of Merck KGaA

    23. Pegfilgrastim Biosimilars Market Future Outlook and Potential Analysis

    23.1. Global Pegfilgrastim Biosimilars Market In 2025 – Countries Offering Most New Opportunities

    23.2. Global Pegfilgrastim Biosimilars Market In 2025 – Segments Offering Most New Opportunities

    23.3. Global Pegfilgrastim Biosimilars Market In 2025 – Growth Strategies

    23.3.1. Market Trend Based Strategies

    23.3.2. Competitor Strategies

    24. Appendix

    24.1. Market Data Sources

    24.2. Research Methodology

    24.3. Currencies

    24.4. Research Inquiries

    24.5. The Business Research Company

    24.6. Copyright and Disclaimer

List Of Tables

    Table 1: Global Pegfilgrastim Biosimilars Market, Historic, 2015 – 2020, $ Million
  • Table 2: Global Pegfilgrastim Biosimilars Market, Forecast, 2020 – 2025, 2030F, $ Million
  • Table 3: Global Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
  • Table 4: Global Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, $ Million
  • Table 5: Global Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
  • Table 6: Global Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic And Forecast, 2015 – 2020, 2025F, 2030F, $ Million
  • Table 7: Global Pegfilgrastim Biosimilars Market, By Region, Historic and Forecast, 2015 – 2020, 2025F, 2030F, %
  • Table 8: Global Pegfilgrastim Biosimilars Market, By Region, Historic and Forecast, 2015 – 2020, 2025F, 2030F, $ Million
  • Table 9: Global Pegfilgrastim Biosimilars Market, By Country, Historic and Forecast, 2015 – 2020, 2025F, 2030F, %
  • Table 10: Global Pegfilgrastim Biosimilars Market, By Country, Historic and Forecast, 2015 – 2020, 2025F, 2030F, $ Million
  • Table 11: Asia Pacific Estimated Average Expenditure, Pegfilgrastim Biosimilar Market, Cancer Prevalence, 2019
  • Table 12: Asia-Pacific Public Healthcare Expenditure, 2015-2020, $ Billion
  • Table 13:  Asia-Pacific Private Healthcare Expenditure, 2015-2020, $ Billion
  • Table 14: Asia Pacific Per Capita Net Disposable Income, 2015-2020, $
  • Table 15: Asia-Pacific, Population By Age Group, By Country, 2015-2025, Thousands
  • Table 16: Asia Pacific GDP Per Capita, 2015-2020, $
  • Table 17: Asia-Pacific, Healthcare Services Market Size, By Country, 2015-2025, $ Billion
  • Table 18: Asia-Pacific Biologics Market Size, 2015-2025, $ Billion
  • Table 19: Asia-Pacific Pegfilgrastim Biosimilars Market, Historic, 2015 – 2020, $ Million
  • Table 20: Asia-Pacific Pegfilgrastim Biosimilars Market, Forecast, 2020 – 2025, 2030F, $ Million
  • Table 21: Asia-Pacific Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
  • Table 22: Asia-Pacific Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, $ Million
  • Table 23: China Estimated Average Expenditure, Pegfilgrastim Biosimilar Market, Cancer Prevalence, 2019
  • Table 24:  China Public Healthcare Expenditure And Private Healthcare Expenditure, 2015-2020, $ Billion
  • Table 25: China Per Capita Net Disposable Income, 2015-2020, $
  • Table 26: China, Population By Age Group, 2015-2025, Thousands
  • Table 27: China GDP Per Capita, 2015-2020, $
  • Table 28: China, Healthcare Services Market Size, By Country, 2015-2025, $ Billion
  • Table 29: China Biologics Market Size, 2015-2025, $ Billion
  • Table 30: China Pegfilgrastim Biosimilars Market, Forecast, 2020 – 2025, 2030F, $ Million
  • Table 31: China Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
  • Table 32: China Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, $ Million
  • Table 33: India Pegfilgrastim Biosimilars Market, Historic, 2015 – 2020, $ Million
  • Table 34: India Pegfilgrastim Biosimilars Market, Forecast, 2020 – 2025, 2030F, $ Million
  • Table 35: India Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
  • Table 36: India Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, $ Million
  • Table 37: Japan Pegfilgrastim Biosimilars Market, Historic, 2015 – 2020, $ Million
  • Table 38: Japan Pegfilgrastim Biosimilars Market, Forecast, 2020 – 2025, 2030F, $ Million
  • Table 39: Japan Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
  • Table 40: Japan Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, $ Million
  • Table 41: Australia Pegfilgrastim Biosimilars Market, Historic, 2015 – 2020, $ Million
  • Table 42: Australia Pegfilgrastim Biosimilars Market, Forecast, 2020 – 2025, 2030F, $ Million
  • Table 43: Australia Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
  • Table 44: Australia Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, $ Million
  • Table 45: Indonesia Pegfilgrastim Biosimilars Market, Forecast, 2020 – 2025, 2030F, $ Million
  • Table 46: Indonesia Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
  • Table 47: Indonesia Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, $ Million
  • Table 48: South Korea Pegfilgrastim Biosimilars Market, Forecast, 2020 – 2025, 2030F, $ Million
  • Table 49: South Korea Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
  • Table 50: South Korea Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, $ Million
  • Table 51: Western Europe Estimated Average Expenditure, Cancer Prevalence, 2019
  • Table 52:  Western Europe Public Healthcare Expenditure, 2015-2020, $ Billion
  • Table 53:  Western Europe Private Healthcare Expenditure, 2015-2020, $ Billion
  • Table 54: Western Europe Per Capita Net Disposable Income, 2015-2020, $
  • Table 55: Western Europe, Population By Age Group, By Country, 2015-2025, Thousands
  • Table 56: Western Europe GDP Per Capita, 2015-2020, $
  • Table 57: Western Europe, Healthcare Services Market Size, By Country, 2015-2025, $ Billion
  • Table 58: Western Europe Biologics Market Size, 2015-2025, $ Billion
  • Table 59: Western Europe Pegfilgrastim Biosimilars Market, Historic, 2015 – 2020, $ Million
  • Table 60: Western Europe Pegfilgrastim Biosimilars Market, Forecast, 2020 – 2025, 2030F, $ Million
  • Table 61: Western Europe Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
  • Table 62: Western Europe Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, $ Million
  • Table 63: UK Pegfilgrastim Biosimilars Market, Historic, 2015 – 2020, $ Million
  • Table 64: UK Pegfilgrastim Biosimilars Market, Forecast, 2020 – 2025, 2030F, $ Million
  • Table 65: UK Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
  • Table 66: UK Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, $ Million
  • Table 67: Germany Pegfilgrastim Biosimilars Market, Historic, 2015 – 2020, $ Million
  • Table 68: Germany Pegfilgrastim Biosimilars Market, Forecast, 2020 – 2025, 2030F, $ Million
  • Table 69: Germany Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
  • Table 70: Germany Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, $ Million
  • Table 71: France Pegfilgrastim Biosimilars Market, Historic, 2015 – 2020, $ Million
  • Table 72: France Pegfilgrastim Biosimilars Market, Forecast, 2020 – 2025, 2030F, $ Million
  • Table 73: France Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
  • Table 74: France Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, $ Million
  • Table 75: Eastern Europe Estimated Average Expenditure, Pegfilgrastim Biosimilar Market, Cancer Prevalence, 2019
  • Table 76:  Eastern Europe Public Healthcare Expenditure, 2015-2020, $ Billion
  • Table 77:  Eastern Europe Private Healthcare Expenditure, 2015-2020, $ Billion
  • Table 78: Eastern Europe Per Capita Net Disposable Income, 2015-2020, $
  • Table 79: Eastern Europe, Population By Age Group, By Country, 2015-2025, Thousands
  • Table 80: Eastern Europe GDP Per Capita, 2015-2020, $
  • Table 81: Eastern Europe, Healthcare Services Market Size, By Country, 2015-2025, $ Billion
  • Table 82: Eastern Europe Biologics Market Size, 2015-2025, $ Billion
  • Table 83: Eastern Europe Pegfilgrastim Biosimilars Market, Forecast, 2020 – 2025, 2030F, $ Million
  • Table 84: Eastern Europe Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
  • Table 85: Eastern Europe Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, $ Million
  • Table 86: Russia Pegfilgrastim Biosimilars Market, Forecast, 2020 – 2025, 2030F, $ Million
  • Table 87: Russia Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
  • Table 88: Russia Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, $ Million
  • Table 89: North America Estimated Average Expenditure, Pegfilgrastim Biosimilar Market, Cancer Prevalence, 2019
  • Table 90:  North America Public Healthcare Expenditure, 2015-2020, $ Billion
  • Table 91:  North America Private Healthcare Expenditure, 2015-2020, $ Billion
  • Table 92: North America Per Capita Net Disposable Income, 2015-2020, $
  • Table 93: North America, Population By Age Group, By Country, 2015-2025, Thousands
  • Table 94: North America GDP Per Capita, 2015-2020, $
  • Table 95: North America, Healthcare Services Market Size, By Country, 2015-2025, $ Billion
  • Table 96: North America Biologics Market Size, 2015-2025, $ Billion
  • Table 97: North America Pegfilgrastim Biosimilars Market, Historic, 2015 – 2020, $ Million
  • Table 98: North America Pegfilgrastim Biosimilars Market, Forecast, 2020 – 2025, 2030F, $ Million
  • Table 99: North America Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
  • Table 100: North America Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, $ Million
  • Table 101: USA Estimated Average Expenditure, Pegfilgrastim Biosimilar Market, Cancer Prevalence, 2019
  • Table 102:  USA Public Healthcare Expenditure And Private Healthcare Expenditure, 2015-2020, $ Billion
  • Table 103: USA Per Capita Net Disposable Income, 2015-2020, $
  • Table 104: USA, Population By Age Group, 2015-2025, Thousands
  • Table 105: USA GDP Per Capita, 2015-2020, $
  • Table 106: USA Home, Healthcare Services Market Size, By Country, 2015-2025, $ Billion
  • Table 107: USA Biologics Market Size, 2015-2025, $ Billion
  • Table 108: USA Pegfilgrastim Biosimilars Market, Historic, 2015 – 2020, $ Million
  • Table 109: USA Pegfilgrastim Biosimilars Market, Forecast, 2020 – 2025, 2030F, $ Million
  • Table 110: USA Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
  • Table 111: USA Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, $ Million
  • Table 112: South America Estimated Average Expenditure, Pegfilgrastim Biosimilar Market, Cancer Prevalence, 2019
  • Table 113:  South America Public Healthcare Expenditure, 2015-2020, $ Billion
  • Table 114:  South America Private Healthcare Expenditure, 2015-2020, $ Billion
  • Table 115: South America Per Capita Net Disposable Income, 2015-2020, $
  • Table 116: South America, Population By Age Group, By Country, 2015-2025, Thousands
  • Table 117: South America GDP Per Capita, 2015-2020, $
  • Table 118: South America, Healthcare Services Market Size, By Country, 2015-2025, $ Billion
  • Table 119: South America Biologics Market Size, 2015-2025, $ Billion
  • Table 120: South America Pegfilgrastim Biosimilars Market, Forecast, 2020 – 2025, 2030F, $ Million
  • Table 121: South America Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
  • Table 122: South America Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, $ Million
  • Table 123: Brazil Pegfilgrastim Biosimilars Market, Forecast, 2020 – 2025, 2030F, $ Million
  • Table 124: Brazil Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
  • Table 125: Brazil Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, $ Million
  • Table 126:  Middle East Public Healthcare Expenditure, 2015-2020, $ Billion
  • Table 127:  Middle East Private Healthcare Expenditure, 2015-2020, $ Billion
  • Table 128: Middle East Per Capita Net Disposable Income, 2015-2020, $
  • Table 129: Middle East, Population By Age Group, By Country, 2015-2025, Thousands
  • Table 130: Middle East GDP Per Capita, 2015-2020, $
  • Table 131: Middle East Healthcare Services Market Size, By Country, 2015-2025, $ Billion
  • Table 132: Middle East Biologics Market Size, 2015-2025, $ Billion
  • Table 133: Middle East Pegfilgrastim Biosimilars Market, Forecast, 2020 – 2025, 2030F, $ Million
  • Table 134: Middle East Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
  • Table 135: Middle East Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, $ Million
  • Table 136:  Africa Public Healthcare Expenditure, 2015-2020, $ Billion
  • Table 137:  Africa Private Healthcare Expenditure, 2015-2020, $ Billion
  • Table 138: Africa Per Capita Net Disposable Income, 2015-2020, $
  • Table 139: Africa, Population By Age Group, By Country, 2015-2025, Thousands
  • Table 140: Africa GDP Per Capita, 2015-2020, $
  • Table 141: Africa Healthcare Services Market Size, By Country, 2015-2025, $ Billion
  • Table 142: Africa Biologics Market Size, 2015-2025, $ Billion
  • Table 143: Africa Pegfilgrastim Biosimilars Market, Forecast, 2020 – 2025, 2030F, $ Million
  • Table 144: Africa Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
  • Table 145: Africa Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, $ Million
  • Table 146: Global Pegfilgrastim Biosimilars Market, Key Competitor Estimated Market Shares, 2019 & 2020, Percentage (%)
  • Table 147: Sandoz (Novartis) – Financial Performance, 2016 – 2020, $ Billion
  • Table 148: Biocon – Financial Performance, 2016 – 2020, $ Billion
  • Table 149: Mylan – Financial Performance, 2016 – 2020, $ Billion
  • Table 150: Intas Biopharmaceuticals Ltd – Financial Performance, 2015 – 2019, $ Billion
  • Table 151: Dr. Reddy’s Laboratories – Financial Performance, 2016 – 2020, $ Billion
  • Table 152: Pfizer Inc. – Financial Overview, 2016 – 2020, $ Billion
  • Table 153: Emcure Pharmaceuticals – Financial Performance, 2016 – 2020, $ Billion
  • Table 154: Global Pegfilgrastim Biosimilars Market, Pipeline Analysis
  • Table 155: Global Pegfilgrastim Biosimilars Market Size Gain ($ Million), 2020 – 2025, By Country
  • Table 156: Global Pegfilgrastim Biosimilars Market Size Gain ($ Million), Segmentation By Application, 2020 – 2025
  • Table 157: Global Pegfilgrastim Biosimilars Market Size Gain ($ Million), Segmentation By Distribution Channel, 2020 – 2025
  • Table 158: Pegfilgrastim Biosimilars - Market Data Sources

List Of Figures

    Figure 1: Global Pegfilgrastim Biosimilars Market Segmentation By Application
  • Figure 2: Global Pegfilgrastim Biosimilars Market Segmentation By Distribution Channel
  • Figure 3: Global Pegfilgrastim Biosimilars Market, Historic, 2015 – 2020, $ Million
  • Figure 4: Global Pegfilgrastim Biosimilars Market, Forecast, 2020 – 2025, 2030F, $ Million
  • Figure 5: Global Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
  • Figure 6: Global Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
  • Figure 7: Global Pegfilgrastim Biosimilars Market, By Region, Historic and Forecast, 2015 – 2020, 2025F, 2030F, %
  • Figure 8: Global Pegfilgrastim Biosimilars Market, By Country, Historic and Forecast, 2015 – 2020, 2025F, 2030F, %
  • Figure 9: Asia-Pacific Pegfilgrastim Biosimilars Market, Historic, 2015 – 2020, $ Million
  • Figure 10: Asia-Pacific Pegfilgrastim Biosimilars Market, Forecast, 2020 – 2025, 2030F, $ Million
  • Figure 11: Asia-Pacific Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
  • Figure 12: China Pegfilgrastim Biosimilars Market, Forecast, 2020 – 2025, 2030F, $ Million
  • Figure 13: China Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
  • Figure 14: India Pegfilgrastim Biosimilars Market, Historic, 2015 – 2020, $ Million
  • Figure 15: India Pegfilgrastim Biosimilars Market, Forecast, 2020 – 2025, 2030F, $ Million
  • Figure 16: India Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
  • Figure 17: Japan Pegfilgrastim Biosimilars Market, Historic, 2015 – 2020, $ Million
  • Figure 18: Japan Pegfilgrastim Biosimilars Market, Forecast, 2020 – 2025, 2030F, $ Million
  • Figure 19: Japan Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
  • Figure 20: Australia Pegfilgrastim Biosimilars Market, Historic, 2015 – 2020, $ Million
  • Figure 21: Australia Pegfilgrastim Biosimilars Market, Forecast, 2020 – 2025, 2030F, $ Million
  • Figure 22: Australia Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
  • Figure 23: Indonesia Pegfilgrastim Biosimilars Market, Forecast, 2020 – 2025, 2030F, $ Million
  • Figure 24: Indonesia Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
  • Figure 25: South Korea Pegfilgrastim Biosimilars Market, Forecast, 2020 – 2025, 2030F, $ Million
  • Figure 26: South Korea Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
  • Figure 27: Western Europe Pegfilgrastim Biosimilars Market, Historic, 2015 – 2020, $ Million
  • Figure 28: Western Europe Pegfilgrastim Biosimilars Market, Forecast, 2020 – 2025, 2030F, $ Million
  • Figure 29: Western Europe Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
  • Figure 30: UK Pegfilgrastim Biosimilars Market, Historic, 2015 – 2020, $ Million
  • Figure 31: UK Pegfilgrastim Biosimilars Market, Forecast, 2020 – 2025, 2030F, $ Million
  • Figure 32: UK Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
  • Figure 33: Germany Pegfilgrastim Biosimilars Market, Historic, 2015 – 2020, $ Million
  • Figure 34: Germany Pegfilgrastim Biosimilars Market, Forecast, 2020 – 2025, 2030F, $ Million
  • Figure 35: Germany Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
  • Figure 36: France Pegfilgrastim Biosimilars Market, Historic, 2015 – 2020, $ Million
  • Figure 37: France Pegfilgrastim Biosimilars Market, Forecast, 2020 – 2025, 2030F, $ Million
  • Figure 38: France Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
  • Figure 39: Eastern Europe Pegfilgrastim Biosimilars Market, Forecast, 2020 – 2025, 2030F, $ Million
  • Figure 40: Eastern Europe Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
  • Figure 41: Russia Pegfilgrastim Biosimilars Market, Forecast, 2020 – 2025, 2030F, $ Million
  • Figure 42: Russia Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
  • Figure 43: North America Pegfilgrastim Biosimilars Market, Historic, 2015 – 2020, $ Million
  • Figure 44: North America Pegfilgrastim Biosimilars Market, Forecast, 2020 – 2025, 2030F, $ Million
  • Figure 45: North America Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
  • Figure 46: USA Pegfilgrastim Biosimilars Market, Historic, 2015 – 2020, $ Million
  • Figure 47: USA Pegfilgrastim Biosimilars Market, Forecast, 2020 – 2025, 2030F, $ Million
  • Figure 48: USA Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
  • Figure 49: South America Pegfilgrastim Biosimilars Market, Forecast, 2020 – 2025, 2030F, $ Million
  • Figure 50: South America Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
  • Figure 51: Brazil Pegfilgrastim Biosimilars Market, Forecast, 2020 – 2025, 2030F, $ Million
  • Figure 52: Brazil Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
  • Figure 53: Middle East Pegfilgrastim Biosimilars Market, Forecast, 2020 – 2025, 2030F, $ Million
  • Figure 54: Middle East Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
  • Figure 55: Africa Pegfilgrastim Biosimilars Market, Forecast, 2020 – 2025, 2030F, $ Million
  • Figure 56: Africa Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
  • Figure 57: Global Pegfilgrastim Biosimilars Market, Key Competitor Estimated Market Shares, 2020, Percentage (%)
  • Figure 58: Global Pegfilgrastim Biosimilars Market, Key Competitor Estimated Market Shares, 2019, Percentage (%)
  • Figure 59 Sandoz (Novartis) – Financial Performance, 2016 – 2020, $ Billion
  • Figure 60: Biocon – Financial Performance, 2016 – 2020, $ Billion
  • Figure 61: Mylan – Financial Performance, 2016 – 2020, $ Billion
  • Figure 62: Intas Biopharmaceuticals Ltd – Financial Performance, 2015 – 2019, $ Billion
  • Figure 63: Dr. Reddy’s Laboratories – Financial Performance, 2016 – 2020, $ Billion
  • Figure 64: Pfizer Inc. – Financial Overview, 2016 – 2020, $ Billion
  • Figure 65: Emcure Pharmaceuticals – Financial Performance, 2016 – 2020, $ Billion
View Report
View Report
View Report
View Report
View Report
View Report
View Report
View Report